top of page
Browse by category
Search


Fractyl Health provides update on clinical studies priorities
Fractyl Health is prioritising its REMAIN-1 pivotal study, addressing the demand for an off-ramp to GLP-1 drugs, while advancing its...


FDA Approves IDE study assessing Revita for weight maintenance after discontinuation of GLP-1
The FDA has approved a pivotal Investigational Device Exemption (IDE) to study the efficacy of Fractyl Health’s Revita system for...
Browse by tag





bottom of page